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Abstract
We explored the relationship of antibodies to the whole
ribosomal P proteins (P0, P1, and P2) in cerebrospinal fluid
(CSF) with diffuse psychiatric/neuropsychological syndromes in
systemic lupus erythematosus (SLE). CSF samples were
obtained from 71 SLE patients (52 patients with diffuse
psychiatric/neuropsychological syndromes [diffuse NP-SLE]
and 19 patients with neurological syndromes or peripheral
neuropathy [focal NP-SLE]) as well as from 24 patients with
non-inflammatory neurological disease. Immunoglobulin G (IgG)
antibodies to the C-terminal 22-amino acid ribosomal P
synthetic peptide (anti-PC22) and those to purified bovine
ribosomal P proteins (P0, P1, and P2) (anti-whole P) were
determined by enzyme-linked immunosorbent assay; affinity-
purified IgG anti-PC22  were used as the standard. The
concentrations of antibodies to epitopes other than the C-
terminal 22 amino acids of ribosomal P proteins were calculated
by subtracting anti-PC22 from anti-whole P (anti-PEX.C22). CSF
anti-whole P levels were significantly elevated in diffuse NP-SLE
compared with focal NP-SLE or control patients. By contrast,
there were no significant differences in CSF anti-PC22 levels
among the three groups. Of note, CSF anti-PEX.C22 levels were
significantly elevated in diffuse NP-SLE compared with the other
two groups. CSF anti-PEX.C22  levels were not significantly
correlated with CSF anti-PC22 levels, but with CSF antibodies
against the recombinant ribosomal P0 protein lacking the C-
terminal 22 amino acids (C22-depleted rP0). Moreover, levels of
CSF anti-PEX.C22 or CSF anti-C22-depleted rP0, but not CSF
anti-PC22, were significantly correlated with CSF anti-neuronal
cell antibodies (anti-N). These results indicate that CSF IgG
antibodies to the epitopes other than the C-terminal 22 amino
acids of ribosomal P proteins, which might contain one of the
major targets of CSF anti-N, are associated with the
development of diffuse NP-SLE.
Introduction
Central nervous system (CNS) involvement is a relatively com-
mon and serious complication of systemic lupus erythemato-
sus (SLE) [1,2]. Previous studies have demonstrated the
association of serum antibodies directed against the C-termi-
nal 22-amino acid sequences of ribosomal P protein (anti-
PC22) with CNS involvement in patients with SLE (neuropsy-
chiatric SLE [NP-SLE]), especially diffuse psychiatric/neu-
ropsychological syndromes (diffuse NP-SLE) [3-5]. However,
the mechanism by which serum anti-PC22 leads to the develop-
ment of diffuse NP-SLE has not yet been elucidated. In fact,
the role of anti-PC22 in the cerebrospinal fluid (CSF) in the
ACR = American College of Rheumatology; anti-C22-depleted rP0 = antibodies directed against recombinant ribosomal P0 protein lacking the C-
terminal 22 amino acids; anti-N = anti-neuronal cell antibodies; anti-PC22 = antibodies directed against the C-terminal 22-amino acid sequences of 
ribosomal P protein; anti-PEX.C22 = autoantibodies directed against the ribosomal P protein epitopes other than the C-terminal 22-amino acid 
sequence; anti-whole P = antibodies to the whole ribosomal P proteins; C22-depleted rP0 = recombinant ribosomal P0 fusion protein lacking the C-
terminal 22 amino acids; CNS = central nervous system; CSF = cerebrospinal fluid; ELISA = enzyme-linked immunosorbent assay; HSA = human 
serum albumin; IgG = immunoglobulin G; IL-6 = interleukin-6; NMDA = N-methyl-d-aspartate; non-CNS SLE = systemic lupus erythematosus without 
neuropsychiatric manifestations; NP-SLE = neuropsychiatric systemic lupus erythematosus; OD492 = optical density at 492 nm; PBS = phosphate-
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pathogenesis with diffuse NP-SLE or even their presence in
the CSF remains uncertain. Thus, Golombek and colleagues
[6] detected the presence of CSF anti-PC22 in all four of the
patients with lupus psychosis in their studies, whereas others
did not [3,4,7].
On the other hand, autoantibodies, which react with the neu-
ronal cell lines or brain tissue, have been reported in the sera
of patients with NP-SLE [8-10]. However, they have been
shown to be present in SLE patients with no clinical evidence
of CNS involvement [10]. In fact, in a cross-sectional study of
SLE patients, no significant association was found between
serum lymphocyte/brain cross-reacting antibodies and NP-
SLE (present in 32% of cases with NP-SLE and 23% of those
without NP-SLE) [10]. Of note, using a radioimmunoassay
with the SK-N-SH neuroblastoma cell as a target, Bluestein
and colleagues [11] demonstrated that immunoglobulin G
(IgG) anti-neuronal cell antibodies (anti-N) were present in
much higher concentrations in the CSF from patients with
active NP-SLE than in the CSF from SLE patients without
active CNS involvement. Using a cell enzyme-linked immuno-
sorbent assay (ELISA) with SK-N-MC neuroblastoma cell lines
fixed with paraformaldehyde, we also confirmed that CSF IgG
anti-N levels were significantly elevated in patients with diffuse
NP-SLE compared with those in SLE patients without diffuse
NP-SLE [7]. However, the fine epitopes to which CSF anti-N
were directed have not yet been delineated.
The presence of the immunodominant C-terminal epitope of
ribosomal P proteins was demonstrated to be present on the
surface of human neuroblastoma cells [12]. However, CSF
anti-PC22 could be detected in only a fraction of patients with
diffuse NP-SLE, whereas almost all the patients with diffuse
NP-SLE expressed CSF anti-N [7]. Of note, previous studies
also demonstrated the presence of a 38-kDa protein that is
closely related to, or identical with, ribosomal P0 protein in
purified human plasma membranes [12]. In addition, it has
been shown that autoantibodies directed against the ribos-
omal P proteins are not only directed against the common C-
terminal 22 amino acids, but against the N-terminal sequence
of the ribosomal P2 or P1 proteins [13]. In fact, recent studies
have revealed that measurement of CSF IgG anti-ribosomal P
protein antibodies with Western blotting using purified ribos-
omes, containing whole ribosomal P0, P1, and P2 proteins,
was more sensitive [14]. Because ribosomal P0 protein con-
tains epitopes other than the C-terminal 22 amino acids, it is
possible that CSF from patients with diffuse NP-SLE contains
antibodies to such epitopes. The current studies, therefore,
were carried out to compare the CSF levels of antibodies to
the whole ribosomal P proteins (anti-whole P) in patients with
diffuse NP-SLE and in patients with focal NP-SLE or non-SLE
non-inflammatory neurological disorders.
Materials and methods
Patients and samples
One hundred and three patients with SLE were included in the
present study. All patients fulfilled the American College of
Rheumatology (ACR) 1982 revised criteria for the classifica-
tion of SLE [15]. Of the 103 patients with SLE, 52 showed dif-
fuse psychiatric/neurological syndromes (diffuse NP-SLE)
according to the 1999 ACR definition of NP-SLE [16], 19
patients showed CNS manifestations other than diffuse NP-
SLE (focal NP-SLE), and 32 patients showed no CNS mani-
festations (non-CNS SLE). Ten of the 52 patients with diffuse
NP-SLE also presented seizures. Because of the difficulties in
confirming the neurological diagnosis and in assigning the
cause to SLE, we defined NP-SLE as (a) the presence of neu-
ropsychiatric manifestations and (b) the elevation of CSF Ig
indices [17,18] and/or the elevation of CSF interleukin-6 (IL-6)
levels [19]. Thus, the 52 patients all showed increased CSF Ig
indices and/or CSF IL-6 in the present study. In addition, 24
patients with non-SLE non-inflammatory neurological diseases
(9 cerebrovascular diseases, 8 cervical spondylosis, 4 degen-
erative diseases, 2 diabetic neuropathy, and 1 epilepsy) were
studied as a control. The 127 patients all gave informed con-
sent, and the study was approved by the institutional ethical
committee of Teikyo University School of Medicine (Tokyo).
The detail and demographic features of the 127 patients are
shown in Table 1. CSF specimens were obtained by a lumbar
puncture when the patients showed active disease. These
samples were kept frozen at -20°C until assayed. All assays
were performed without knowledge of the diagnosis or clinical
presentations.
Human anti-PC22 sera and affinity purification of anti-PC22
IgG fractions were purified from the anti-PC22-positive sera of
SLE patients by means of a protein G-Sepharose 4FF column
(Amersham Pharmacia Biotech, now part of GE Healthcare,
Little Chalfont, Buckinghamshire, UK). Anti-PC22 were purified
from the IgG fractions of SLE sera by means of an N-hydroxy-
succinimide-activated Sepharose HP column (GE Healthcare)
coupled with synthetic ribosomal P peptide-human serum
albumin (HSA) conjugates as previously described [20]. Anti-
PC22 thus purified reacted strongly with ribosomal P peptide-
HSA conjugates, but not with HSA alone in an ELISA. It was
also confirmed on Western blot analysis that purified anti-PC22
reacted with native ribosomal P proteins (P0, P1, and P2)
(data not shown).
Measurement of autoantibodies to ribosomal P proteins
Antibodies for the C-terminal 22-amino acid ribosomal P syn-
thetic peptide (anti-PC22) in sera and CSF and those for puri-
fied whole ribosomal P proteins (anti-whole P) in CSF were
determined by specific ELISA using the highly purified syn-
thetic C-terminal 22-amino acid ribosomal P peptide conju-
gated to HSA as an antigen as previously described [5] and
highly purified bovine ribosomal P proteins (P0, P1, and P2)
(purity of more than 90%) (Arotec Diagnostics Limited, Wel-Available online http://arthritis-research.com/content/9/3/R44
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lington, New Zealand). Antibodies for the epitope representing
regions of the ribosomal P proteins other than PC22 were sim-
ilarly determined by ELISA using recombinant ribosomal P0
fusion protein lacking the C-terminal 22 amino acids (C22-
depleted rP0) as previously described [21].
Briefly, wells of a 96-well microtiter plate were coated with
ribosomal P peptide-HSA conjugates at 15 μg/ml or highly
purified bovine ribosomal P proteins at 1.0 μg/ml in phos-
phate-buffered saline (PBS) (pH 7.2) or C22-depleted rP0 at
5 μg/ml in 6 M urea/10 mM Tris-HCl (pH 7.5) with 2 mM 2-
mercaptoethanol (coating buffer) at 4°C overnight. Each well
was then overcoated with Block Ace (Dainippon Pharmaceu-
tical, Osaka, Japan), diluted 1:4 with PBS. Prior to being
added to the antigen-coated wells, serum and CSF samples
were usually diluted 1:200 and 1:2, respectively, in PBS con-
taining 1% bovine serum albumin (Miles, now part of Bayer
Corp., Emeryville, CA, USA). Bound antibody was detected
with peroxidase-conjugated F (ab')2 fragments of goat anti-
human IgG (MP Biochemicals, Solon, OH, USA). After incuba-
tion with substrate solution containing 60 mg of o-phenylene-
diamine and 10 μl of 30% H2O2 in 100 ml of 0.05 M citrate
phosphate buffer (pH 4.8) at 37°C for 30 minutes, the reaction
was stopped by addition of 5 N H2SO4, and the absorbance
(optical density) at 492 nm (OD492) was read with a two-wave-
length microplate photometer (MTP-120; Corona Electric Co.,
Ltd., Ibaraki, Japan). Determinations of OD492 were normalized
to affinity-purified anti-PC22 such that anti-PC22 and anti-whole
P activity might be converted to micrograms per milliliter of
IgG. Antibodies directed against C22-depleted rP0 (anti-C22-
depleted rP0) were expressed by arbitrary unit designation
using a standard serum.
Non-specific binding activities to HSA for anti-PC22 or those to
wells with PBS alone or coating buffer alone for anti-whole P
or anti-C22-depleted rP0 were also determined in reference to
the standard curves for binding activities to ribosomal P pep-
tide (PC22)-HSA conjugates, highly purified ribosomal P pro-
teins, or C22-depleted rP0. The specific anti-PC22, anti-whole
P, or anti-C22-depleted rP0 activities were thus determined by
subtracting the values for the non-specific binding activity from
those for binding activity to PC22-HSA conjugates or to highly
purified ribosomal P proteins or C22-depleted rP0. The intra-
assay and interassay variances (coefficient of variation values)
for anti-whole P were 13.8% and 15.7%, respectively, and
those for anti-PC22 were previously described [7].
Measurement of anti-N
Anti-N in the CSF samples were determined by a cell ELISA
using human neuroblastoma cell line SK-N-MC as previously
Table 1
Profiles of the patients studied
Diagnosis Number of patients Gender (male/female) Age in years (mean ± SD)
SLE 103
Diffuse NP-SLE 52 4/48 37.8 ± 14.2
Acute confusional state 20
Anxiety disorder 3
Cognitive dysfunction 10a
Mood disorder 12b
Psychosis 7
Focal NP-SLE 19 2/17 39.0 ± 14.8
Cerebrovascular disease 6
Headache 2
Movement disorder 1
Seizure disorder 6
Polyneuropathy 4
Non-CNS SLE 32 3/29 42.7 ± 13.9
Non-SLE control 24 22/2 48.0 ± 13.7
aOne patient also presented mood disorder. bOne patient also presented cognitive dysfunction. Non-CNS SLE, systemic lupus erythematosus 
without neuropsychiatric manifestations; NP-SLE, neuropsychiatric systemic lupus erythematosus; SD, standard deviation; SLE, systemic lupus 
erythematosus.Arthritis Research & Therapy    Vol 9 No 3    Hirohata et al.
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described [7]. Briefly, SK-N-MC cells were seeded at a den-
sity of 5 × 104 per well in wells of a flat-bottomed 96-well
tissue culture plate (no. 3596; Costar, now part of Corning
Life Sciences, Acton, MA, USA) for 48 hours, after which the
cells were fixed with 1% paraformaldehyde in PBS for 5 min-
utes at 37°C. After three washes with PBS containing 0.05%
Tween 20, 50 μl of the appropriately diluted samples or vari-
ous concentrations of standard sera were added and the
plates were incubated for 1 hour at 37°C. Bound IgG anti-N
were detected with peroxidase-conjugated F(ab')2 fragments
of goat anti-human IgG as previously described [7]. Determi-
nation of OD492 was normalized to standard sera for anti-N
obtained from patients with diffuse NP-SLE such that anti-N
activity might be converted to an arbitrary unit scale. The con-
centration of anti-N that produced half of the maximal absorb-
ance at 492 nm, given by the saturating concentration of anti-
N in the cell ELISA plate, was arbitrarily defined as 1 U/ml [7].
Statistical analysis
Differences in CSF anti-PC22, anti-whole P, anti-PEX.C22, and
anti-C22-depleted rP0 among various groups were analyzed
by Kruskal-Wallis test with multiple comparison (Scheffe's
method). The correlation of anti-PC22 levels with anti-PEX.C22 or
anti-C22-depleted rP0 levels and the correlation of anti-N lev-
els with anti-PC22, anti-PEX.C22, or anti-C22-depleted rP0 levels
were evaluated by Spearman rank correlation test. Differences
in serum anti-PC22, anti-whole P, and anti-PEX.C22  levels
between non-CNS SLE and NP-SLE were analyzed by
Welch's t test.
Results
Initial experiments examined CSF anti-PC22 levels in the three
groups of patients. Although anti-PC22 levels in CSF appeared
to be higher in diffuse NP-SLE, there were no significant differ-
ences in their levels among the three groups, including diffuse
NP-SLE, focal NP-SLE, and non-inflammatory neurological
control (Figure 1a). The results therefore confirm the previous
observation that CSF anti-PC22 might not be prevalent in dif-
fuse NP-SLE. By contrast, anti-whole P levels in CSF from
patients with diffuse NP-SLE were significantly elevated com-
pared with those from patients with focal NP-SLE or with non-
inflammatory neurological diseases (Figure 1b). In addition, it
should be noted that CSF anti-whole P levels were signifi-
cantly higher than CSF anti-PC22 levels in 67 patients with dif-
fuse NP-SLE and focal NP-SLE (P < 0.0001 as evaluated by
Wilcoxon signed rank test). These results suggest that in addi-
tion to anti-PC22, CSF from patients with NP-SLE might con-
tain autoantibodies that recognize ribosomal P protein
epitopes other than the C-terminal 22-amino acid sequence.
To explore in detail the prevalence of the autoantibodies
directed against the ribosomal P protein, epitopes other than
the C-terminal 22-amino acid sequence (anti-PEX.C22) were
calculated by subtracting anti-PC22 from anti-whole P. As can
be seen in Figure 1c, anti-PEX.C22 levels in CSF from patients
with diffuse NP-SLE were significantly elevated compared
with those from patients with focal NP-SLE or with non-inflam-
matory neurological diseases. As shown in Figure 2, there was
no significant correlation between CSF anti-PC22 and CSF
anti-PEX.C22  levels, obviating the possibility that CSF anti-
PEX.C22 activities might result from contamination of CSF anti-
PC22 in patients with SLE. These results indicate that autoanti-
bodies directed against ribosomal P protein epitopes other
than the C-terminal 22-amino acid sequence are strongly
associated with the development of diffuse NP-SLE.
Moreover, the data indicate that the expression of such
Figure 1
Cerebrospinal fluid antibodies to various components of ribosomal P proteins Cerebrospinal fluid antibodies to various components of ribosomal P proteins. CSF antibodies to the C-terminal 22-amino acid sequence of ribos-
omal P protein (anti-PC22), highly purified ribosomal P proteins (anti-whole P), and epitopes other than the C-terminal 22-amino acid sequence (anti-
PEX.C22). Anti-PC22 (a), anti-whole P (b), and anti-PEX.C22 (c) in CSF from patients with non-inflammatory neurological diseases (Control), with diffuse 
neuropsychiatric systemic lupus erythematosus (NP-SLE), or with focal NP-SLE were compared. Horizontal lines indicate the mean values. Statisti-
cal analysis was performed by Kruskal-Wallis test with multiple comparisons (Scheffé's method). CSF, cerebrospinal fluid; N.S., not significant.Available online http://arthritis-research.com/content/9/3/R44
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autoantibodies in CSF is not related to the presence of anti-
PC22 in CSF.
To confirm the presence of autoantibodies to ribosomal P pro-
tein epitopes other than the C-terminal 22-amino acid
sequence, IgG antibodies to recombinant ribosomal P0 pro-
tein lacking the C-terminal 22 amino acids (C22-depleted rP0)
were examined in CSF from 65 SLE patients with neuropsy-
chiatric manifestations. Affinity-purified anti-PC22 reacted with
ribosomal P peptide-HSA conjugates, but not with C22-
depleted rP0, confirming the lack of the C-terminal 22-amino
acid sequence in the C22-depleted rP0 (Figure 3). As shown
in Figure 4, CSF anti-C22-depleted rP0 levels were signifi-
cantly correlated with CSF anti-PEX.C22 levels in these 65
patients. In addition, anti-C22-depleted rP0 levels in CSF from
patients with diffuse NP-SLE were significantly elevated com-
pared with those from patients with focal NP-SLE or with non-
inflammatory neurological diseases (Figure 5). Accordingly,
the frequency of positive expression of anti-C22-depleted rP0
in CSF from patients with diffuse NP-SLE was higher than that
in CSF from patients with focal NP-SLE or with non-inflamma-
tory neurological diseases (Table 2). These results confirm the
presence of autoantibodies to ribosomal P protein epitopes
other than the C-terminal 22-amino acid sequence.
We next examined whether CSF anti-whole P might account
for anti-N activities in CSF from patients with NP-SLE. As
shown in Table 3, levels of CSF anti-whole P and anti-PC22
as well as CSF anti-N were decreased when CSF was incu-
bated with paraformaldehyde-fixed SK-N-MC cells for 120
minutes at room temperature, confirming that CSF anti-whole
P or anti-PC22 are constituents of CSF anti-N. However, as
shown in Figure 6a, CSF anti-N levels were not significantly
correlated with CSF anti-PC22 levels in SLE patients, includ-
ing those with diffuse NP-SLE and focal NP-SLE. By contrast,
CSF anti-N levels were significantly correlated with CSF anti-
PEX.C22 or CSF anti-C22-depleted rP0 levels (Figure 6b,c
Finally, we examined serum levels of anti-PC22, anti-whole P,
and anti-PEX.C22 in patients with non-CNS SLE or with NP-
SLE. The values of anti-PC22, anti-whole P, and anti-PEX.C22 in
24 patients with non-SLE non-inflammatory neurological dis-
eases were 2.44 ± 2.92 μg/ml, 4.92 ± 6.51 μg/ml, and 3.41
± 6.06 μg/ml (mean ± standard deviation), respectively. As
shown in Figure 7, serum anti-PC22 as well as anti-whole P lev-
els in NP-SLE were significantly elevated compared with those
in non-CNS SLE, which is consistent with previous studies [3-
5]. Serum anti-PC22 and anti-whole P levels appeared to be
higher in diffuse NP-SLE than those in focal NP-SLE, although
Figure 2
Correlation between autoantibodies to various components of ribos- omal P proteins Correlation between autoantibodies to various components of ribos-
omal P proteins. The correlation between antibodies to the C-terminal 
22-amino acid sequence of ribosomal P protein (anti-PC22) and those 
to the ribosomal P protein epitopes other than the C-terminal 22-amino 
acid sequence (anti-PEX.C22) in cerebrospinal fluid from patients with 
systemic lupus erythematosus (SLE), including 52 patients with diffuse 
neuropsychiatric SLE (NP-SLE) and 19 patients with focal NP-SLE, 
was analyzed. Statistical analysis was performed by Spearman rank 
correlation test.
Table 2
Summary of the frequency of positive expression of antibodies to various ribosomal P protein components in cerebrospinal fluida
Percentage positiveb
Control Diffuse NP-SLE Focal NP-SLE
Anti-PC22 4.2% (1/24) 23.1% (12/52) 5.3% (1/19)
Anti-whole P 0% (0/24) 78.8% (41/52) 31.6% (6/19)
Anti-PEX.C22 4.2% (1/24) 65.4% (34/52) 26.3% (5/19)
Anti-C22-depleted rP0 5.3% (1/19) 44.7% (21/47) 5.6% (1/18)
aAntibodies to the C-terminal 22-amino acid sequence of ribosomal P protein (anti-PC22), to highly purified ribosomal P proteins (anti-whole P), to 
the epitopes other than the C-terminal 22-amino acid sequence (anti-PEX.C22), and to recombinant ribosomal P0 protein lacking the C-terminal 22-
amino acid sequence (anti-C22-depleted rP0) in cerebrospinal fluid from patients with non-inflammatory neurological diseases (Control), with 
diffuse neuropsychiatric systemic lupus erythematosus (NP-SLE), or with focal NP-SLE were compared. bCutoff values were set as the mean + 3 
standard deviations of the values in control group. Values in parenthesis mean (numbers of patients with positive results/total patient numbers) in 
each group.Arthritis Research & Therapy    Vol 9 No 3    Hirohata et al.
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there were no statistical significances by Kruskal-Wallis test
with multiple comparisons. Of note, there were no significant
differences in serum anti-PEX.C22 levels between non-CNS
SLE and NP-SLE. These results suggest that in contrast with
the CSF results, serum anti-PC22, but not serum anti-P). The
data therefore suggest that C22-depleted rP0 might contain
one of the major targets, against which CSF anti-N are
directed.EX.C22, are associated with NP-SLE, especially diffuse
NP-SLE.
Discussion
A number of studies have suggested that CSF anti-N play an
important role in the pathogenesis of diffuse NP-SLE [7,11].
However, the epitopes to which CSF anti-N are directed have
not been delineated. Of note, previous studies have demon-
strated that epitopes antigenically related to ribosomal P pro-
teins are present on the surface of SK-N-MC neuroblastoma
cells [12]. Although anti-PC22 have been shown to be major
autoantibodies to ribosomal P proteins [3,4,22], the frequency
of their detection in CSF from patients with diffuse NP-SLE
was not high enough to ensure their involvement in the patho-
genesis of this disease [3,4,7]. Therefore, it was suggested
that anti-PC22 might not be a major constituent of anti-N in CSF
from patients with diffuse NP-SLE. Consistently, the data in
the current studies indicated that CSF anti-PC22 levels were
not significantly elevated in patients with diffuse NP-SLE com-
pared with those in patients with focal NP-SLE or with non-
inflammatory neurological diseases. However, it was still pos-
sible that CSF autoantibodies directed to ribosomal P protein
epitopes other than the C-terminal 22-amino acid sequence
were more prevalent. Thus, the results in the current studies
have also demonstrated that levels of CSF anti-whole P as well
as CSF anti-PEX.C22 were significantly higher in patients with
diffuse NP-SLE than in patients with focal NP-SLE or non-
inflammatory neurological diseases. The data therefore indi-
cate that CSF antibodies to ribosomal P protein epitopes
other than the C-terminal 22-amino acid sequence are associ-
ated with diffuse NP-SLE.
To confirm the presence of antibodies for the epitopes repre-
senting regions of the ribosomal P proteins other than the C-
terminal 22-amino acid sequence, antibodies to recombinant
ribosomal P0 protein lacking the C-terminal 22 amino acids
(C22-depleted rP0) [21] were evaluated. The results clearly
demonstrate that CSF anti-C22-depleted rP0 levels were sig-
nificantly correlated with CSF anti-PEX.C22 levels. In addition,
levels of CSF anti-C22-depleted rP0 as well as CSF anti-
PEX.C22 were significantly elevated in diffuse NP-SLE. The data
therefore confirm that CSF antibodies to ribosomal P protein
epitopes other than the C-terminal 22-amino acid sequence
play a role in the pathogenesis of diffuse NP-SLE, but further
studies are required to identify the fine epitopes.
Figure 3
Differential reactivity of purified antibodies to the C-terminal 22 amino  acids of ribosomal P protein Differential reactivity of purified antibodies to the C-terminal 22 amino 
acids of ribosomal P protein. Differential reactivity of purified antibodies 
to the C-terminal 22-amino acid sequence of ribosomal P protein (anti-
PC22) with ribosomal P peptide-human serum albumin (HSA) conju-
gates and with recombinant ribosomal P0 protein lacking the C-termi-
nal 22-amino acid sequence (C22-depleted rP0). Purified anti-PC22 
react with ribosomal P peptide-HSA conjugates, but not with C22-
depleted rP0 on enzyme-linked immunosorbent assay plates. OD492 
(optical density at 492 nm) values that are subtracted by non-specific 
binding activities are plotted.
Figure 4
Correlation between autoantibodies to various components of ribos- omal P proteins Correlation between autoantibodies to various components of ribos-
omal P proteins. The correlation between antibodies to recombinant 
ribosomal P0 protein lacking the C-terminal 22-amino acid sequence 
(anti-C22-depleted rP0) and those to the ribosomal P protein epitopes 
other than the C-terminal 22-amino acid sequence (anti-PEX.C22) in cer-
ebrospinal fluid patients, including 47 patients with diffuse neuropsy-
chiatric systemic lupus erythematosus (NP-SLE) and 18 patients with 
focal NP-SLE, was analyzed. Statistical analysis was performed by 
Spearman rank correlation test.Available online http://arthritis-research.com/content/9/3/R44
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In has been demonstrated that purified human plasma mem-
branes contain a 38-kDa protein that is closely related or iden-
tical to ribosomal P0 proteins [12]. Therefore, it was
suggested that autoantibodies to ribosomal P proteins,
especially those directed to epitopes other than the C-terminal
22-amino acid sequence, might be involved (at least in part) in
CSF anti-N activities. In fact, levels of CSF anti-PEX.C22 as well
as CSF anti-PC22 or CSF anti-whole P were decreased after
incubation of CSF with paraformaldehyde-fixed SK-N-MC
cells, confirming that CSF anti-PEX.C22 as well as anti-PC22 are
constituents of CSF anti-N. However, CSF anti-PC22 levels
were not significantly correlated with CSF anti-N levels in the
present study. By contrast, CSF anti-PEX.C22 or CSF anti-C22-
depleted rP0 levels were significantly correlated with CSF
anti-N levels. These results indicate that ribosomal P0 proteins
contain one of the major targets of CSF anti-N in their portions
other than the C-terminal 22-amino acid sequence. Of note,
recent studies have demonstrated that autoantibodies
directed against the N-methyl-d-aspartate (NMDA) receptor
mediated apoptotic death of neurons in vivo and in vitro in
murine systems [23]. Of note, anti-NMDA receptor antibodies
were also detected in CSF from a single patient with SLE [22].
It is therefore likely that anti-NMDA receptor antibodies might
also be involved in CSF anti-N activities and thus play a pivotal
role in the pathogenesis of diffuse NP-SLE. Further studies
with a large number of patients are required to confirm the
involvement of anti-NMDA receptor antibodies in diffuse NP-
SLE and to explore its relationship with anti-N.
A number of studies have indicated that serum anti-ribosomal
P protein antibodies, including anti-PC22 or anti-whole P, are
frequently observed in patients with NP-SLE [3-5,24]. Con-
sistently, the results in the current studies have also disclosed
that levels of serum anti-PC22 as well as serum anti-whole P are
significantly higher in NP-SLE than those in non-CNS SLE. Of
Figure 5
Cerebrospinal fluid antibodies to recombinant ribosomal P0 protein  lacking the C-terminal 22-amino acid sequence Cerebrospinal fluid antibodies to recombinant ribosomal P0 protein 
lacking the C-terminal 22-amino acid sequence. Antibodies to recom-
binant ribosomal P0 protein lacking the C-terminal 22-amino acid 
sequence (anti-C22-depleted rP0) (U/ml) in cerebrospinal fluid from 
patients with non-inflammatory neurological diseases (Control), with dif-
fuse neuropsychiatric systemic lupus erythematosus (NP-SLE), or with 
focal NP-SLE were compared. Horizontal lines indicate the mean val-
ues. Statistical analysis was performed by Kruskal-Wallis test with mul-
tiple comparisons (Scheffé's method). N.S., not significant.
Table 3
Absorption of CSF autoantibodies to various components of ribosomal P proteins by neuronal cells
Patient Autoantibodies Without absorption With absorption
1A n t i - w h o l e  P  ( μg/ml) 7.243 1.435
Anti-PC22 (μg/ml) 3.456 1.019
Anti-PEX.C22 (μg/ml) 3.787 0.416
Anti-N (U/ml) 4.083 1.950
2A n t i - w h o l e  P  ( μg/ml) 0.140 0.050
Anti-PC22 (μg/ml) 0.070 0.042
Anti-PEX.C22 (μg/ml) 0.070 0.008
Anti-N (U/ml) 0.789 0.588
Cerebrospinal fluid (CSF) samples (50 μl/well) were incubated in wells of a 96-well flat-bottomed microtiter plate with or without confluent SK-N-
MC cells fixed with 1% paraformaldehyde at room temperature for 2 hours. After the incubation, CSF samples were recovered and were examined 
for anti-whole P, anti-PC22, anti-PEX.C22, and anti-N as described in Materials and methods. Anti-N, anti-neuronal cell antibodies; anti-PC22, 
antibodies directed against the C-terminal 22-amino acid sequences of ribosomal P protein; anti-PEX.C22, autoantibodies directed against the 
ribosomal P protein epitopes other than the C-terminal 22-amino acid sequence; anti-whole P, antibodies to the whole ribosomal P proteins.Arthritis Research & Therapy    Vol 9 No 3    Hirohata et al.
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note, serum anti-PEX.C22 levels were not significantly elevated
in NP-SLE compared with those in non-CNS SLE. These find-
ings contrast sharply with the results of CSF studies. Thus, in
CSF, anti-PEX.C22, but not anti-PC22, were significantly associ-
ated with diffuse NP-SLE, whereas in serum, anti-PC22, but not
anti-PEX.C22, were associated with NP-SLE.
The mechanism by which anti-whole P cause neuronal dam-
age remains unclear. We previously reported that the expres-
sion of IL-6 mRNA in neurons was upregulated in the brain of
an SLE patient who died of active diffuse NP-SLE [25]. Of
note, we recently disclosed that anti-PC22  upregulate the
expression of mRNAs for IL-6 and tumor necrosis factor-alpha
in human peripheral blood monocytes [20]. It should be
pointed out that anti-PEX.C22 as well as anti-PC22 might be able
to bind the ribosomal P protein on neuronal cells [12]. Taken
together, these results suggest that anti-whole P or anti-
PEX.C22 might also upregulate the expression of IL-6 mRNA in
neurons and thus result in the alteration of their functions. Fur-
ther studies to explore the targets and the effects on their func-
tions of anti-PC22 and anti-PEX.C22 (or anti-PAA9) would improve
our understanding of the pathogenesis of NP-SLE.
In summary, the current studies have demonstrated that the
expression of autoantibodies directed against the epitopes of
ribosomal P proteins other than the C-terminal 22-amino acid
sequence is increased in CSF from patients with diffuse NP-
SLE. The presence of such autoantibodies might account for
CSF anti-N activities, although there might be other antibodies
that bind to neuronal cells, such as anti-NMDA receptor anti-
bodies. Further studies to explore the whole spectrum of
epitopes of neurons to which autoantibodies are directed as
well as the mechanism by which such autoantibodies cause
damage to neurons are needed for a complete understanding
of the pathogenesis of diffuse NP-SLE.
Conclusion
The present study has disclosed that CSF IgG antibodies to
the epitopes of ribosomal P0 proteins other than the C-termi-
nal 22 amino acids are associated with the development of dif-
fuse NP-SLE as one of the major CSF anti-N components.
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Figure 6
Correlation between autoantibodies to ribosomal P proteins and anti- neuronal cell antibodies Correlation between autoantibodies to ribosomal P proteins and anti-
neuronal cell antibodies. The correlation of antibodies to the C-terminal 
22-amino acid sequence of ribosomal P proteins (anti-PC22) (a), those 
to the ribosomal P protein epitopes other than the C-terminal 22-amino 
acid sequence (anti-PEX.C22) (b), or those to recombinant ribosomal P0 
protein lacking the C-terminal 22-amino acid sequence (anti-C22-
depleted rP0) (c) with anti-neuronal cell antibodies (anti-N) in cerebros-
pinal fluid from systemic lupus erythematosus (SLE) patients, including 
52 patients (a,b) or 47 patients (c) with diffuse neuropsychiatric SLE 
(NP-SLE) and 19 patients (a,b) or 18 patients (c) with focal NP-SLE, 
was analyzed. Statistical analysis was performed by Spearman rank 
correlation test.Available online http://arthritis-research.com/content/9/3/R44
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